Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Ken Hatogai"'
Autor:
Andrea Ziblat, Brendan L. Horton, Emily F. Higgs, Ken Hatogai, Anna Martinez, Jason W. Shapiro, Danny E.C. Kim, YuanYuan Zha, Randy F. Sweis, Thomas F. Gajewski
Publikováno v:
Cell Reports, Vol 43, Iss 5, Pp 114141- (2024)
Summary: The cellular source of positive signals that reinvigorate T cells within the tumor microenvironment (TME) for the therapeutic efficacy of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade has not been clearly defined. We n
Externí odkaz:
https://doaj.org/article/478fd475a2364a4cb4cfc24d76e04912
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/46f9a67d69e64210831aa2db379797ab
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/5cb7497e72c74b24a7a92a9984b2bef1
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/e671f367a1734d8080a95a896cf17c37
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/f9e279c1b9724561b39c21d3d4952698
Autor:
Craig Labbate, Ken Hatogai, Ryan Werntz, Walter M. Stadler, Gary D. Steinberg, Scott Eggener, Randy F. Sweis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Abstract Background Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivolumab and ipilimumab h
Externí odkaz:
https://doaj.org/article/d5be1d58c2bd4f0dab13fa116eaaa105
Autor:
H. Kim Lyerly, Jun Ren, Renzo Canetta, Gi Hyun Kim, Sumimasa Nagai, Tomohiro Yamaguchi, Ken Hatogai, Hiroshi Katayama, Silvy Da Rocha Dias, Daniel McManus, Kathy Soltys, Zhimin Yang, Olufumilayo Olopade, Nancy Goodman, Greg Reaman, Thomas Gross
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-11 (2018)
Advances in genetic sequencing and other diagnostic technologies have enabled the use of precision medicine in clinical cancer care, as well as the development of novel therapies that are targeted to specific molecular drivers of cancer. Developing t
Externí odkaz:
https://doaj.org/article/46a7ce1f1bc64090b5009fbf969ef5cc
Autor:
Andrew X. Zhu, Richard S. Finn, Anran Wang, Ken Hatogai, Michael Chisamore, Abby B. Siegel, Shukui Qin, Jennifer J. Knox, Stephen L. Chan, Bruno Daniele, Sadahisa Ogasawara, Ann-Lii Cheng, Masatoshi Kudo, Stephane Cattan, Julien Edeline, Arndt Vogel, Daniel H. Palmer, Debashis Sarker, Per Stal, Vittorina Zagonel, Adel Kardosh, Hans Van Vlierberghe, Chris Verslype, Mark Karwal, Ivan Borbath, Gontran Verset
Supplementary Table from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baebad0607bff4283e57c19482ca76af
https://doi.org/10.1158/1078-0432.22487739.v1
https://doi.org/10.1158/1078-0432.22487739.v1
Autor:
Andrew X. Zhu, Richard S. Finn, Anran Wang, Ken Hatogai, Michael Chisamore, Abby B. Siegel, Shukui Qin, Jennifer J. Knox, Stephen L. Chan, Bruno Daniele, Sadahisa Ogasawara, Ann-Lii Cheng, Masatoshi Kudo, Stephane Cattan, Julien Edeline, Arndt Vogel, Daniel H. Palmer, Debashis Sarker, Per Stal, Vittorina Zagonel, Adel Kardosh, Hans Van Vlierberghe, Chris Verslype, Mark Karwal, Ivan Borbath, Gontran Verset
Supplementary Data from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f878324f4138a41d0d21b069afb2bed
https://doi.org/10.1158/1078-0432.22487754.v1
https://doi.org/10.1158/1078-0432.22487754.v1
Autor:
Andrew X. Zhu, Richard S. Finn, Anran Wang, Ken Hatogai, Michael Chisamore, Abby B. Siegel, Shukui Qin, Jennifer J. Knox, Stephen L. Chan, Bruno Daniele, Sadahisa Ogasawara, Ann-Lii Cheng, Masatoshi Kudo, Stephane Cattan, Julien Edeline, Arndt Vogel, Daniel H. Palmer, Debashis Sarker, Per Stal, Vittorina Zagonel, Adel Kardosh, Hans Van Vlierberghe, Chris Verslype, Mark Karwal, Ivan Borbath, Gontran Verset
Supplementary Figure from Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::228278ca47c25847032b382978f7e5b7
https://doi.org/10.1158/1078-0432.22487748
https://doi.org/10.1158/1078-0432.22487748